Souhaitez-vous accéder aux communiqués récents ?

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to...

Shareholders approve 21st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow  Dr. Joerg Reinhardt...

Aktionäre genehmigen für 2017 die 21. Dividendenerhöhung in Folge auf CHF 2,80 pro Aktie (+2%) - dies entspricht einer Rendite von 3,6% und einer Ausschüttungsquote von rund 67% des Free Cashflow ...

Les actionnaires approuvent la 21e hausse consécutive du dividende, à CHF 2,80 (+2 %) par action au titre de l'exercice 2017, soit un rendement de 3,6 % et une distribution du free cash-flow...

Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis  Collaboration combines Novartis' leadership...

Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo    CLAIM is the first study to investigate the...

Majority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1]  Scalp psoriasis affects 60 million people...

Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1]   Findings show absolute PASI...

Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis  Cryptosporidiosis is the...

Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL  Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in...